Company news

Liquidia Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million

January 8, 2023

Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)

December 4, 2022

Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 7, 2022

Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022

October 31, 2022

Precedential Opinion Panel Denies United Therapeutics’ Request for Review of ‘793 Inter Partes Review Decision

October 26, 2022

Liquidia Announces Presentations at the CHEST 2022 Annual Meeting

October 16, 2022

Liquidia Provides Update on Hatch-Waxman Litigation and to Host Call on September 1, 2022, at 8: 00am E.T.

August 30, 2022

Liquidia Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 10, 2022

Liquidia to Report Second Quarter 2022 Financial Results on August 11, 2022

August 3, 2022

Liquidia to Participate in Upcoming Investor Conferences

July 31, 2022

Liquidia Announces the Publication of Long-Term Clinical Data from Completed INSPIRE Study in the Journal Pulmonary Circulation

July 31, 2022

Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

July 20, 2022

Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent

July 18, 2022

Liquidia Corporation Added to Russell 2000® and 3000® Indexes

June 26, 2022

Liquidia Appoints Rajeev Saggar, M.D., as Chief Medical Officer

June 19, 2022

Liquidia Announces Presentation at the 2022 Pulmonary Hypertension Association (PHA) International Conference

June 8, 2022

Update to Liquidia’s Participation in the Jefferies Healthcare Conference

June 6, 2022

Liquidia to Participate in the Jefferies Healthcare Conference

June 1, 2022

Liquidia Announces Presentations at the 2022 American Thoracic Society (ATS) International Conference

May 15, 2022

Liquidia Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 11, 2022

Liquidia to Report First Quarter 2022 Financial Results on May 12, 2022

May 4, 2022

Liquidia Announces Oral Presentation at the 42nd Annual Meeting of International Society for Heart and Lung Transplant (ISHLT)

April 19, 2022

Liquidia Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option

April 17, 2022

Liquidia Announces Proposed Offering of Common Stock

April 11, 2022

Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

March 21, 2022

Liquidia Corporation Reports Full-Year 2021 Financial Results and Provides Corporate Update

March 16, 2022

Liquidia Corporation to Report Full Year 2021 Financial Results on Thursday, March 17, 2022

March 9, 2022

Liquidia Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 22, 2022

Liquidia Re-Finances Debt Facility With Silicon Valley Bank To Increase To $40.0 Million

January 6, 2022

Liquidia Corporation Announces Chief Executive Officer Transition

January 2, 2022

Stipulation of Partial Judgment In Favor of Liquidia Filed In Hatch-Waxman Litigation

December 28, 2021

Liquidia to Participate in the Jefferies London Healthcare Conference

November 10, 2021

FDA Grants Tentative Approval for Liquidia’s YUTREPIA™ (Treprostinil) Inhalation Powder

November 7, 2021

Liquidia Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 2, 2021

Liquidia to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

September 9, 2021

FDA Completes On-site Pre-Approval Inspection of Liquidia’s Morrisville, North Carolina Facility

August 17, 2021

U.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes Review of United Therapeutics’ Tyvaso® Patent

August 11, 2021

Liquidia Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 9, 2021

Liquidia to Report Second Quarter 2021 Financial Results on August 10, 2021

August 2, 2021

Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder

June 1, 2021

Liquidia Corporation To Present At The Jefferies Virtual Healthcare Conference

May 25, 2021

Liquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration

May 23, 2021

Liquidia Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 12, 2021

Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension

May 9, 2021

Liquidia Corporation to Report First Quarter 2021 Financial Results on May 13, 2021

May 5, 2021

Liquidia Corporation Announces $21.7 Million Private Placement

April 12, 2021

Liquidia Corporation To Present At The 20th Annual Needham Virtual Healthcare Conference

April 6, 2021

Liquidia Announces Generic Treprostinil Injection Will Be Available for Subcutaneous Route of Administration

March 29, 2021

Liquidia Corporation Reports Full-Year 2020 Financial Results and Provides Corporate Update

March 22, 2021

Liquidia Corporation to Host 2020 Financial Results Conference Call on March 23, 2021

March 8, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 9 decks. Every deck is listed under its year.